Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non-Current Deffered Revenue: 2012-2013

Historic Non-Current Deffered Revenue for Catalyst Pharmaceuticals (CPRX) over the last 1 years, with Dec 2013 value amounting to $19,131.

  • Catalyst Pharmaceuticals' Non-Current Deffered Revenue fell 12.56% to $19,131 in Q4 2013 from the same period last year, while for Dec 2013 it was $19,131, marking a year-over-year decrease of 12.56%. This contributed to the annual value of $19,131 for FY2013, which is 12.56% down from last year.
  • As of Q4 2013, Catalyst Pharmaceuticals' Non-Current Deffered Revenue stood at $19,131, which was down 4.54% from $20,040 recorded in Q3 2013.
  • Catalyst Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $21,878 during Q4 2012, with a 5-year trough of $19,131 in Q4 2013.
  • Its 2-year average for Non-Current Deffered Revenue is $20,426, with a median of $20,346 in 2013.
  • Data for Catalyst Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY declined of 12.56% (in 2013) over the last 5 years.
  • Over the past 2 years, Catalyst Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $21,878 in 2012, then decreased by 12.56% to $19,131 in 2013.
  • Its Non-Current Deffered Revenue was $19,131 in Q4 2013, compared to $20,040 in Q3 2013 and $20,653 in Q2 2013.